RESUMO
Since the introduction of antiretroviral therapy (ART), persons living with HIV (PLHIV) are traveling more frequently and international travel has become much safer. Specific concerns include the safety of ART during travel, drug adherence and interactions. The simultaneous administration of ART and antimalarial drugs is a challenge, considering the lack of reliable data. Several travel-related infectious diseases are more frequent and/or more severe in PLHIV. Even with a CD4 count > 400/microl, some PLHIV experience lower immune responses to several vaccines. With avanced immunosuppression, complications following the administration of live vaccines can occur, and most of the responses to vaccine are clearly reduced. The consequences of reduced vaccine immunogenicity on their clinical effectiveness (protection against infection) are unclear.
